Mycobacterium tuberculosis is one of the most important diseases around the world. About two billion people are infected, 10 % develop the active disease and more than two million people die annuallyReference Dye1. Macrophages eliminate mycobacteria when activated by interferon (IFN)-γ produced by T lymphocytesReference Flynn and Chan2. However, some bacilli resist killing and survive within macrophages, leading to the active form of the diseaseReference Mueller and Pieters3. Mycobacteria avoid phagosome maturation and inhibit bacterial antigen presentation, suppress macrophage apoptosis and modulate the production of down-regulating cytokines, such as IL-10, transforming growth factor β, which, in turn, inhibit IFN-γ production by T cells and macrophage activationReference Mustafa, Mogga, Mfinanga, Morkve and Sviland4. The severity of tuberculosis (TB) is increased by several immunodeficiency diseases; the most important is HIV/AIDSReference Silversides5. Malnutrition is another important cause of immunodeficiency that increases the risk for TBReference Cegielski and McMurray6, which is particularly found in developing countries. Individuals with TB present deficiencies of micronutrients, including antioxidantsReference Madebo, Lindtjorn, Aukrust and Berge7. Patients with TB from Ethiopia were found to have significantly lower concentrations of vitamins C, E and A in their serum than healthy volunteersReference Madebo, Lindtjorn, Aukrust and Berge7. In another study of patients with TB from Indonesia, the authors reported that the nutritional status of patients suffering from TB was poor in comparison with healthy controls. Patients were anaemic and exhibited low plasma concentrations of retinol and ZnReference Karyadi, Schultink, Nelwan, Gross, Amin, Dolmans, van der Meer, Hautvast and West8. Protein malnutrition also alters the abilities of cells to produce cytokines, including IFN-γ, TNF-α and transforming growth factor β in response to purified protein derivative (PPD)Reference Chan, Tian, Tanaka, Tsang, Yu, Salgame, Carroll, Kress, Teitelbaum and Bloom9, Reference Dai and McMurray10. Nutrition has been recognized as an important way to modulate the immune response. Some nutrients have shown the ability to alter the production of cytokinesReference Loscher, Draper, Leavy, Kelleher, Mills and Roche11–Reference Zhang, Smith, Chapkin and McMurray13. Vitamin E increased the proliferation of lymphocytes and production of IL-2 in elderly people, as well as in experimental models of aged animalsReference Meydani, Barklund, Liu, Meydani, Miller, Cannon, Morrow, Rocklin and Blumberg14, Reference Moriguchi, Kobayashi and Kishino15. Vitamin E supplementation has been reported to enhance the production of IFN-γReference Han, Wu, Ha, Beharka, Smith, Bender and Meydani16, Reference Malmberg, Lenkei, Petersson, Ohlum, Ichihara, Glimelius, Frodin, Masucci and Kiessling17. The aim of this work was to test whether the addition of vitamin E would alter the proliferation and cytokine production of peripheral blood mononuclear cells (PBMC) from TB patients when stimulated with PPD or phytohaemagglutinin (PHA).
Methods
Seven patients suffering from TB were diagnosed based on clinical, radiological and bacteriological data by the medical staff of the Department of Health of the state of Sonora, following international criteria. Five men (60·2 (sd 15·6) years old) and two women (50·2 (sd 19·2) years old), with pulmonary TB and under treatment were included in the study. Healthy volunteers (n 7) were matched to the patients by age and gender. Patients and volunteers received 0·1 ml (5 units) PPD (Tubersol®; Aventis Pasteur Limited, Ontario, Canada) intradermally. The induration was measured at 72 h and recorded as the average of two perpendicular diameters on mmReference Bouros, Zeros, Panaretos, Vassilatos and Siafakas18. Patients and volunteers presented a positive skin reaction to intradermal PPD injection (5·7 (sd 3) mm and 26 (sd 4) mm of reaction in patients and volunteers, respectively). All patients and volunteers were vaccinated with BCG (TB vaccine) when born. All subjects signed a letter of consent to participate in the protocol, which was approved by the ethics committee of the institution and the corresponding state health authorities, following international regulations. Criteria of inclusion were HIV-negative, non-pregnant women, cancer free, not alcohol or drug consumers and not taking a vitamin E supplement. For in vitro supplementation, a stock solution of vitamin E was prepared by dissolving α-tocopherol in absolute ethanol. To optimize cellular uptake, vitamin E was then mixed with inactivated fetal bovine serum (16000-044; GIBCO, Grand Island, NY, USA) at a final concentration of 2·31 mm and incubated at 37°C for 1 h in the dark with intermittent vortexing. For supplementation of PBMC, vitamin E was prepared in RPMI-1640 (R4130; Sigma, St Louis, MO, USA) with 10 % fetal bovine serum at a final concentration of 50 μm for 4 h. We chose this concentration based upon previous reportsReference Adolfsson, Huber and Meydani19. Before stimulation, cells were washed and resuspended in fresh medium without vitamin E.
Blood (15 ml) was collected into heparin-coated blood collection tubes (Becton-Dickinson, San Jose, CA, USA), overlaid with an equal volume of Ficoll-Hypaque (17-144-02; Amersham Biosciences, Uppsala, Sweden) and centrifuged at 500 g for 20 min. PBMC were collected from the interface, washed three times in RPMI-1640 and cell viability was determined by the trypan blue dye exclusion method. Cell proliferation was evaluated by [3H]thymidine uptake. A total of 2500 PBMC were placed into 96-well plates (3596; Corning, NY, USA) in a final volume of 200 μl RPMI-1640 medium supplemented with 10 % heat-inactivated fetal bovine serum, 50 mm-2-mercaptoethanol (M7522; Sigma), 100 UI penicillin/ml and 100 μg streptomycin/ml (P4458; Sigma). The cells were stimulated with PHA (12 μg/ml) or PPD (10 μg/ml) for 6 d at 37°C in a 5 % CO2 humidified atmosphere. Before collection (18 h), cells were pulsed with 1 μCi [3H]thymidine and then collected with a multiple cell harvester (Titratek) onto glass microfibre filter paper (Whatman, Maidstone, Kent, UK). The paper was dried, immersed in vials containing scintillation fluid and the DNA-incorporated radioactivity was measured in a Beckman LS 5000 counter (Beckman Coulter, Fullerton, CA, USA). Results are expressed as counts per min. Serum samples were collected from blood (8 ml), frozen at − 70°C and protected from the light until α-tocopherol quantification. The α-tocopherol was quantified from serum and 4 × 106 supplemented or not supplemented PBMC, as described previouslyReference Hess, Keller, Oberlin, Bonfanti and Schuep20 with some modifications. The HPLC quantification consisted of a Varian Solvent Delivery module Pro-Star 220, a variable wavelength UV-Vis detector (Model 9050; Varian, Walnut Creek, CA, USA) and a Microsorv C-18 column (R-0089200E3; Varian). The mobile phase was methanol–water (98:2) and detection limit was 0·02 ug/ml. Flow cytometry analysis of intracellular cytokine production by PHA- or PPD-stimulated PBMC was performed as previously describedReference Garfias, Ortiz, Hernandez, Magana, Becerril-Angeles, Zenteno and Lascurain21 and analysed using CellQuest® software or WinMDI (http://facs.scripps.edu/software.html). The concentration of IFN-γ in the supernatant of PHA- or PPD-stimulated PBMC was determined according to manufacturer's recommendations. Data are expressed as means and standard deviations. Statistical analysis of the data was performed by two-way ANOVA followed by Tukey's test to evaluate differences and interactive effects between vitamin E supplementation and TB patients on several responses (PPD stimulus and unstimulated on proliferation, cell producing cytokines and IFN-γ). Student t test was used to analyse the serum concentration of vitamin E on TB patients and healthy volunteers. All analysis was done using the NCSS 2000 package (v.2007, Kaysville, UT, USA).
Results
Serum vitamin E status in TB patients and healthy volunteers was 2·0 (sd 0·8) μg/ml (range 0·82–3·66 μg/ml) and 2·9 (sd 1·1) μg/ml (range 0·87–4·83 μg/ml), respectively. A significant difference (P ≤ 0·05) was observed between TB patients and healthy volunteers. Proliferation of PBMC from TB patients (Table 1) was not significantly different (P ≥ 0·05) with regard to non-stimulated cells; however, proliferation increased significantly (3·3 fold difference, P ≤ 0·05) in the presence of vitamin E. Proliferation of PBMC from healthy PPD+ volunteers was higher as compared with non-stimulated cells (P ≤ 0·05), but, in this case, vitamin E did not increase proliferation (P ≥ 0·05). When comparing the PPD-induced proliferation between healthy PPD+ volunteers and TB patients, it was 3·1 fold higher in healthy volunteers (P ≤ 0·05). No proliferation was observed in unstimulated cells cultured with vitamin E (Table 1). The percentage of cells producing IL-2 (Fig. 1) was higher in PHA-stimulated PBMC than in cells stimulated with PPD or non-stimulated cells (P ≤ 0·05); similarly, the percentage of cells producing IL-2 was higher in those stimulated with PPD than in non-stimulated cells (P ≤ 0·05). These findings were similar in patients and healthy PPD+ volunteers. PBMC from healthy PPD+ volunteers showed an increase in the percentage of cells producing IL-2 in the presence of vitamin E, but this difference was not statistically significant (P ≥ 0·05). The percentage of cells producing IFN-γ was similar to that of IL-2-producing cells. However, patients with TB showed a lower number of IFN-γ-producing cells when stimulated with PHA or PPD as compared with healthy PPD+ volunteers, although the difference was not statistically significant. As described for IL-2, vitamin E did not increase the percentage of IFN-γ-producing cells in healthy PPD+ volunteers stimulated with PPD (P ≥ 0·05). No changes were observed when IFN-γ was quantified by ELISA in the supernatant of either patients or healthy PPD+ volunteers (Fig. 2; P ≥ 0·05). Before supplementation, the α-tocopherol concentration was similar in PBMC from patients and from healthy PPD+ volunteers. After supplementation, α-tocopherol content increased significantly (P ≤ 0·05) in the cells of both patients and healthy PPD+ volunteers. No statistically significant differences were observed between patients and healthy PPD+ volunteers with regard to the α-tocopherol status of their cells (Fig. 3).
a,b Mean values within a column with unlike superscript letters were significantly different (P ≤ 0·05). Statistical analyses were performed using two-way ANOVA followed by Tukey's multiple comparison test.
* Mean values were significantly different between TB patients and healthy PPD+ volunteers. P values were 0·001004 for vitamin E supplementation, 0·0182 for presence of TB and 0·173517 for vitamin E × presence of TB.
† For details of subjects and procedures, see Methods.
Discussion
The ability of vitamin E to modulate the immune response has been demonstrated previouslyReference Meydani, Barklund, Liu, Meydani, Miller, Cannon, Morrow, Rocklin and Blumberg14–Reference Malmberg, Lenkei, Petersson, Ohlum, Ichihara, Glimelius, Frodin, Masucci and Kiessling17, Reference Adolfsson, Huber and Meydani19, Reference Li-Weber, Giaisi, Treiber and Krammer22. These effects include an increase in proliferation of PBMC and production of IL-2 in vitro Reference Adolfsson, Huber and Meydani19 and in vivo in human subjectsReference Malmberg, Lenkei, Petersson, Ohlum, Ichihara, Glimelius, Frodin, Masucci and Kiessling17, a decrease of IL-4 in vitro in human subjectsReference Li-Weber, Giaisi, Treiber and Krammer22 and, in some cases, an increase in IFN-γ in vivo in human subjects and miceReference Han, Wu, Ha, Beharka, Smith, Bender and Meydani16, Reference Malmberg, Lenkei, Petersson, Ohlum, Ichihara, Glimelius, Frodin, Masucci and Kiessling17, Reference Han, Adolfsson, Lee, Prolla, Ordovas and Meydani23 or in vitro in young but not in aged miceReference Han, Adolfsson, Lee, Prolla, Ordovas and Meydani23. Considering these findings, we hypothesized that vitamin E could exert the same effects on PBMC from patients with TB. To test this hypothesis, we evaluated whether vitamin E supplementation would increase proliferation or/and cytokine production (IL2 and IFN-γ) in PBMC from TB patients. As previously describedReference Madebo, Lindtjorn, Aukrust and Berge7, serum α-tocopherol was lower (P ≤ 0·05) on TB patients than on healthy volunteers; in contrast, content in PBMC did not show differences between groups. These results suggest that the lower serum vitamin E did not affect the concentration at cellular level. However, in vitro supplementation increased the content of vitamin E on PBMC from TB patients and healthy volunteers. It was interesting to find that vitamin E resulted in higher PPD-induced PBMC proliferation in TB patients, but no changes were observed in PPD+ healthy volunteers. To determine if this increase was associated with the production of IL-2 or IFN-γ, we evaluated the number of cytokine-producing cells. The cells were cultured for 24 h and the results revealed no significant changes in the number of cells producing IL-2 or IFN-γ from patients stimulated with PPD in the presence of vitamin E (P ≥ 0·05). In addition, no significant changes were observed on the IFN-γ detected in the supernatant of cultured cells.
The ability of α-tocopherol to neutralize oxygen intermediariesReference Singh, Devaraj and Jialal24 and to increase the normal function of the immune system are its most important propertiesReference Meydani, Han and Wu25. Vitamin E increases the humoral and cellular immune response. In the cellular immune response, the effects include enhanced proliferation of T cells and production of IL-2Reference Adolfsson, Huber and Meydani19. This characteristic has been observed in human subjects and in other speciesReference Meydani, Barklund, Liu, Meydani, Miller, Cannon, Morrow, Rocklin and Blumberg14, Reference Moriguchi, Kobayashi and Kishino15, Reference Adolfsson, Huber and Meydani19. In human subjects, vitamin E is especially important in restoring the immune function of aged people. In this population, the increased production of PGE2 by macrophages is reduced through vitamin E supplementationReference Wu, Mura, Beharka, Han, Paulson, Hwang and Meydani26, thereby removing the inhibitory PGE2 effects. Vitamin E also increased the expression of cell-related genes such as cyclin B, Cdc2 and Cdc6, which are important in the regulation of cell cycle of the cellsReference Han, Adolfsson, Lee, Prolla, Ordovas and Meydani23, and improves age-related early T cell signalling in naïve CD4 T cellsReference Marko, Ahmed, Bunnell, Wu, Chung, Huber and Meydani27. We observed that TB patients had diminished reaction to PPD skin test and low PPD-induced PBMC proliferation. Similar results have been observed in other reports, in which they suggest an erroneous immune response provoked by an imbalance in the production of T-helper 1 and T-helper 2 cytokinesReference Sanchez, Rodriguez, Agudelo and Garcia28, Reference Ottenhoff, Verreck, Hoeve and van de Vosse29. In agreement with the former study, the present results showed that vitamin E increases PBMC proliferation in TB patients stimulated with PPD, but not in PBMC from healthy PPD+. An important challenge will be to test if vitamin E is able to reverse this phenomenon in vivo. Considering that proliferation is associated with production of IL-2, we expected increases of this cytokine, but we did not observe differences. A possibility for this disagreement is that we only evaluated the number of cells producing IL-2 and not production of IL-2 protein. Previous assessments of the effects of vitamin E on mice have been focused on the increase in IL-2 production (protein and intracellular expression), as well as on the increment in the number of IL-2-producing cellsReference Adolfsson, Huber and Meydani19.
Other effects of vitamin E include the reduction of IL-4 at the transcriptional level by blocking NF-κB and activating protein-1Reference Li-Weber, Giaisi, Treiber and Krammer22, as well as increasing IFN-γReference Han, Wu, Ha, Beharka, Smith, Bender and Meydani16, Reference Malmberg, Lenkei, Petersson, Ohlum, Ichihara, Glimelius, Frodin, Masucci and Kiessling17. The IFN-γ increase has been described in a mouse modelReference Han, Wu, Ha, Beharka, Smith, Bender and Meydani16, Reference Han, Adolfsson, Lee, Prolla, Ordovas and Meydani23 and in some patients with colorectal cancerReference Malmberg, Lenkei, Petersson, Ohlum, Ichihara, Glimelius, Frodin, Masucci and Kiessling17 who were supplemented with 750 mg vitamin E for 2 weeks. This latter study showed that vitamin E effects include increments in the proportion of CD4:CD8 T cells and IL-2 production. However, it is not yet completely understood how vitamin E controls the production of IFN-γ, but evidence suggests that vitamin E is able to modulate the balance T-helper-1/T-helper-2Reference Li-Weber, Giaisi, Treiber and Krammer22, Reference Han, Adolfsson, Lee, Prolla, Ordovas and Meydani23. We expected an increase in the production of IFN-γ in the presence of vitamin E but vitamin E effects were not statistically significant. Future studies must evaluate other concentrations of vitamin E to identify whether these results could represent a significant difference.
In summary, the present work shows that vitamin E enhances the PPD-induced proliferation of PBMC from TB patients, but no changes in cytokine production were observed. We are currently performing experiments in our laboratory to determine how vitamin E could modulate the immune response in patients with TB.
Acknowledgements
We thank Dr David McMurray for many helpful comments, suggestions and critical reading of the manuscript. We also thank Mónica Reséndiz for technical assistance, Laboratorio Ramos and M.C. Alfonso Ramos for the support in the use of the flow cytometry and all personnel from the Secretaría de Salud del Estado de Sonora for their assistance in the localization of patients, especially to Dr Tania Fontes and Dr José Esquivel. This work was a grant from Fondos Sectoriales Salud-CONACYT project No. SALUD-2004-CO1-0108 and Fondos Mixtos Sonora-CONACYT project No. SON-2004-C01-025.